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Abstract
Background: Mathematical models based on kinetics of HIV-1 plasma viremia after initiation of
combination antiretroviral therapy (cART) inferred HIV-infected cells to decay exponentially with
constant rates correlated to their strength of virus production. To further define in vivo decay
kinetics of HIV-1 infected cells experimentally, we assessed infected cell-classes of distinct viral
transcriptional activity in peripheral blood mononuclear cells (PBMC) of five patients during 1 year
after initiation of cART
Results: In a novel analytical approach patient-matched PCR for unspliced and multiply spliced viral
RNAs was combined with limiting dilution analysis at the single cell level. This revealed that HIV-
RNA+ PBMC can be stratified into four distinct viral transcriptional classes. Two overlapping cell-
classes of high viral transcriptional activity, suggestive of a virion producing phenotype, rapidly
declined to undetectable levels. Two cell classes expressing HIV-RNA at low and intermediate
levels, presumably insufficient for virus production and occurring at frequencies exceeding those of
productively infected cells matched definitions of HIV-latency. These cells persisted during cART.
Nevertheless, during the first four weeks of therapy their kinetics resembled that of productively
infected cells.
Conclusion:  We have observed biphasic decays of latently HIV-infected cells of low and
intermediate viral transcriptional activity with marked decreases in cell numbers shortly after
initiation of therapy and complete persistence in later phases. A similar decay pattern was shared
by cells with greatly enhanced viral transcriptional activity which showed a certain grade of levelling
off before their disappearance. Thus it is conceivable that turnover/decay rates of HIV-infected
PBMC may be intrinsically variable. In particular they might be accelerated by HIV-induced
activation and reactivation of the viral life cycle and slowed down by the disappearance of such
feedback-loops after initiation of cART.
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Background
Current combination antiretroviral therapy (cART) does
not attack virus-infected cells themselves but targets viral
replication at major steps in the viral life cycle [1]. Thus,
the decline of HIV-1 plasma viremia induced by cART has
been interpreted to reflect cell-specific decay rates of HIV-
infected cells with different life-spans and rates of virus
production [2,3]: A first phase of decay, perceptible within
the first weeks of cART, has been attributed to the initial
loss of productively infected activated T-lymphocytes.
Due to their intrinsically short life-span [4] and to direct
viral and immunity-mediated cytopathic effects [5], these
cells are prone for rapid cell-death.
Later phases of decay were thought to reflect expanded
life-spans of virus producing macrophages or memory T-
lymphocytes [5]. In addition, latently infected cells reacti-
vated to productivity, may also contribute to the pool of
HIV-virions observed in later decay phases [2,3]. When
viremia levels fall below the threshold of detection, per-
sisting infection is primarily due to a long lived reservoir
of latently infected CD4+ cells [6-8].
Mathematical models based on plasma viremia only indi-
rectly allow inferring kinetics of latently infected cells
which lack virus production. Direct quantification of
latently infected cells ex vivo has commonly been attained
by viral outgrowth assays of resting CD4+-T-lymphoctyes
[6]. These bioassays relying on inducibility and longevity
of donor and indicator cells may underestimate numbers
of latently infected cells. Accordingly, their frequencies
during cART have been estimated to be very low, in the
order of 1 in 106 lymphocytes [8]. Further characterization
of the cells constituting the latent reservoirs has revealed
that only a very low percentage of resting CD4 T-cells car-
rying HIV-DNA can be induced ex vivo to give rise to viral
transcription[9] or antigen production [10].
This contrasts with comparatively high levels of cell-asso-
ciated viral RNA (hundreds to thousands of viral RNA
copies/106 cells) observed in peripheral blood of patients
on cART, even in the absence of detectable plasma viremia
[11-14]. Recently, evidence has accumulated that HIV-
RNA persisting during cART may to a large extent reflect
basal transcription in latently infected cells devoid of vir-
ion production [9,12,15-17]. Such bulk measurements of
cellular HIV-1 RNAs, despite their potential to monitor
viral activity far beyond undetectable viremia [15], have
considerable shortcomings, namely their lack of unam-
biguous differentiation between viral transcription in
latently versus productively infected cells.
In the present study we refined the analysis of HIV-tran-
scription, by combining highly sensitive PCR assays for a
panel of unspliced (UsRNA) and multiply spliced
(MsRNA) HIV-RNA species with limiting dilution end-
point analysis of PBMC. Using this approach, we were
able to dissect the population of HIV-RNA+ PBMC accord-
ing to their level of viral transcription and to determine
frequencies and kinetics of cells expressing proviral DNA
at different rates.
Results
Analysis of HIV-1 transcription in serial dilutions of PBMC
Individually adjusted RT-PCR targeting HIV-1 nucleic
acids was performed on serial dilutions of PBMC assessing
HIV-DNA, UsRNA, total MsRNA and MsRNA-tatrev or
MsRNA-nef [15]. In parallel to testing total RNA extracts,
vRNA-ex representing cell-associated viral particles, was
quantified in separate replicate specimens [12,18]. Limit-
ing dilution analysis of HIV-RNA+ cells was performed to
compute their frequencies which also allowed determin-
ing the average per-cell expression of HIV-RNA.
As shown in figure 1A, the numbers of cells expressing
UsRNA or MsRNA experienced significant decreases (p =
0.0006) as a result of antiretroviral treatment while
decrease of total HIV-infected PBMC was less pronounced
(p = 0.14). Paired analysis throughout the course of obser-
vation (one-way Anova-Friedman test, comparison of fre-
quencies of HIV-DNA+, UsRNA+, MsRNA+, vRNA+ cells
per patient and per time-point; p < 0.0001) showed that
total HIV-infected PBMC exceeded cells expressing viral
RNA, which revealed a preponderance of transcriptionally
silent provirus in peripheral blood. Moreover, cells
expressing UsRNA were invariably more frequent than
cells expressing MsRNA and the latter were more frequent
than cells positive for UsRNA-ex. These findings provide
evidence for the existence of cells expressing solely UsRNA
and cells expressing MsRNA and presumably also UsRNA
and a third very rare population of cells positive for vRNA-
ex.
To further characterize HIV-RNA expression, average
intracellular per-cell expression of UsRNA and MsRNA
was calculated by normalizing RNA copy numbers to fre-
quencies of total HIV-infected PBMC (figure 1B) or to
cells actually expressing viral RNA (figure 1C). Using
either mode of calculation, per-cell expression of MsRNA
was significantly lower in samples obtained during cART
as compared to samples from untreated patients (total
cells: 4-fold decrease; p = 0.002; figure 1B, HIV-RNA+ cells
9-fold decrease; p = 0.0004; figure 1C). Reduction of per-
cell UsRNA-expression during treatment attained high sta-
tistical significance when normalized to total HIV-
infected PBMC (20-fold; p < 0.0001; figure 1B) but was
perceptible only as a trend when UsRNA-expression was
normalized to UsRNA+ cells (1.2-fold, p = 0.14; figure
1C). Thus, per-cell MsRNA expression and to a lesser
extent also UsRNA-expression appeared to split up into
two discernible states. From these findings the following
implications can be inferred:Retrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
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i) Several classes of HIV-infected cells differing in their
viral transcriptional activity co-occur before therapy. After
initiation of cART cells with lower RNA content appear to
outlast cells expressing higher levels of viral RNA.
ii) Three cell classes can be dissected directly using limit-
ing cell-dilution, by virtue of their hierarchical distribu-
tion of frequencies: a class which expresses solely UsRNA,
one class expressing MsRNA and presumably also UsRNA
and a class of cells positive for vRNA-ex.
iii) Cells expressing MsRNA may host one or more sub-
categories of infected cells with lower and higher viral
transcriptional activity.
A model for stratification of viral RNA content in HIV-1 
infected PBMC
To account for the observed complexity of HIV-RNA
expression in PBMC, we designed a simple model to
resolve and identify cell categories of different transcrip-
tional states. In particular, the data presented above sug-
gest the coexistence of four main classes of HIV-RNA+ cells
namely, ILow (low transcriptional activity), IIMedium (inter-
mediate transcriptional activity), IIHigh (high transcrip-
tional activity) and IIIExtra(ongoing extracellular virion
shedding).
ILow
HIV-1 infected cells containing solely UsRNA. The existence
of this cell class is deduced from our observations that
UsRNA-positive cells were invariably more frequent than
cells expressing MsRNA.
IIMedium
HIV-1 infected cells expressing MsRNA at low levels. Evidence
for this class of cells is based on significant differences in
per-cell MsRNA content in PBMC from patients on cART
as compared to untreated patients. It is highly likely that
such cells express UsRNA because MsRNAs are obligato-
rily derived from primary unspliced HIV-transcripts [19].
IIHigh
HIV-1 infected cells with elevated viral transcription. Signifi-
cantly higher relative expression of both UsRNA and
Antiretroviral therapy mediated decreases in HIV-infected cells and average cellular viral transcriptional activity Figure 1
Antiretroviral therapy mediated decreases in HIV-infected cells and average cellular viral transcriptional activ-
ity. HIV-RNA (UsRNA, MsRNA, vRNA-ex), HIV-DNA levels and frequencies of PBMC positive for HIV-RNAs were measured 
before start of cART (grey boxes) and at six time-points during treatment (white boxes). Signature signifies the type of viral 
nucleic acid measured for determination of infected cell-numbers. Sample sizes in each group (n = sample numbers, analysis of 
5 patients, one time point before cART, six time-points during therapy, only data of time points with PCR-positive samples 
were included) are indicated below diagrams and p-values of Mann-Whitney comparison of treated versus untreated groups 
are indicated above. Groups are displayed as "box and whiskers" showing the median, 75% percentiles and range of each data 
set. A: Frequencies of total infected PBMC, as represented by HIV-DNA levels and frequencies of PBMC expressing viral RNAs 
determined by limiting dilution as described in figure 2. (B: Average per-cell expression of intracellular viral RNAs (UsRNA, 
MsRNA) normalized to HIV-DNA (representing the total number of HIV-infected cells). C: Average per-cell expression of 
intracellular viral RNAs normalized to the numbers of PBMC expressing viral RNA. To favour sampling of balanced average 
populations, solely viral RNA measurements from specimens containing more than 106 PBMC were analyzed in B and C (n = 2–
6 per time-point and patient).
101
R
N
A
-
c
o
p
i
e
s
/
D
N
A
 
c
o
p
i
e
s
100
10-1
10-2
10-3
10-4
18
R
N
A
-
c
o
p
i
e
s
/
U
s
-
R
N
A
+
c
e
l
l
103
102
101
100
10-1
R
N
A
-
c
o
p
i
e
s
/
M
s
-
R
N
A
+
c
e
l
l
103
102
101
100
10-1
UsRNA MsRNA
-+ + -
119 92 18
Signature:
cART:
n= 5
UsRNA vRNA-ex
-+ + -
28 10 5 5
HIV-DNA
-+
30 18
UsRNA MsRNA
-+ + -
119 92 18
104
H
I
V
+
 
c
e
l
l
s
/
1
0
6
P
B
M
C
103
102
101
100
10-1
p=0.0004
p=0.14
p<0.0001
p=0.002
p=0.0006
p=0.0006
p=0.14
B: Viral intracellular RNA normalized
to total HIV-infected cells
A: Frequencies of PBMC
positive for HIV-1 nucleic acids
C: Viral intracellular RNA normalized
to cells expressing HIV-RNA
p=0.003
MsRNA
5
-+
30Retrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
Page 4 of 16
(page number not for citation purposes)
MsRNA in untreated versus treated patients, suggests fre-
quent presence of cells exhibiting Tat/Rev-mediated tran-
scriptional activation [20,21] at baseline.
IIIExtra
Cells carrying virion-enclosed HIV-1 RNA. Such cells to a
major extent represent productively infected cells in a
state of ongoing or recent burst of viral shedding as previ-
ously demonstrated by their association with activated
viral transcription [12,15,16].
Applying distinct criteria as compiled in table 1, allowed
to calculate the number of cells allocated to each cell-class
for each specimen containing viral RNA. Thus frequencies
of cell-classs were calculated during the course of cART. By
using our dataset comprising 476 HIV-RNA+ specimens of
total RNA extracts, relative per-cell expression of UsRNA
and MsRNA in the three transcriptional categories ILow,
IIMedium and IIHigh could be calculated as outlined in figure
2.
Distinct transcriptional signatures of HIV-infected PBMC
Analysis of viral RNA per-cell contents (figure 3) con-
firmed that relative expression of HIV-RNA increased in
the three transcriptional categories ILow, IIMedium and IIHigh.
Median viral RNA expression ranged from 3.7 HIV-RNA
copies/cell in class-ILow to 15 copies/cell in class-IIMedium
and to 333 copies/cell in class-IIHigh. Notably, in class-IIMe-
dium  UsRNA expression was approximately four times
higher than MsRNA expression (p < 0.0001, Wilcoxon
signed rank test), whereas class-IIHigh showed an inverse
pattern with MsRNA expression equaling or slightly
exceeding UsRNA expression (p = 0.06; Wilcoxon signed
rank test). Thus class-IIMedium and class-IIHigh displayed dif-
ferent viral transcriptional signatures.
To further validate our stratification of HIV-infected
PBMC, relative RNA contents of UsRNA and MsRNA in
ILow, IIMedium  and IIHigh  were compared in specimens
obtained prior to and during therapy. In the stratum with
basal viral transcription of exclusively UsRNA (ILow), per-
cell viral RNA contents did not differ between baseline
and cART (geometric mean, 95%CI, baseline = 2.1, 1.1–
3.9 copies/cell; n = 22; on cART = 3.1, 2.4–4.0 copies/cell;
n = 158, Mann Whitney test p = 0.22) indicating that this
cell-class did not comprise additional subcategories. Sim-
ilarly, in class IIMedium cells, per cell content of UsRNA plus
MsRNA did not reveal a statistically significant difference
when baseline samples were compared to specimens
obtained during cART (geometric mean, 95%CI, baseline
= 26, 13–47 copies/cell; n = 26, on cART = 14, 11–18 cop-
ies/cell; n = 170, Mann Whitney test p = 0.06). Since sam-
ples obtained during cART also comprised study week 2,
when plasma viremia had not yet stabilized, we also per-
formed comparison of baseline samples to cART without
the specimens from week 2. Similarly this analysis did not
reveal statistically significant differences between the two
groups (data not shown, Mann-Whitney test, p = 0.11).
Thus, viral RNA expression in class-IIMedium cells did not
experience evident changes during the course of antiretro-
viral therapy.
Conversely, viral RNA content was 5× higher (Mann Whit-
ney test p < 0.0001) in class-IIHigh at baseline (geometric
mean, 95%CI= 532, 334–846 copies/cell; n = 50) as com-
pared to on-therapy samples (geometric mean, 95%CI =
102, 66–158 copies/cell, n = 50).
This shows that categorization of cells expressing MsRNA
into the classes IIMedium and IIHigh was still not sufficient to
delineate the full scale of viral transcriptional patterns. On
a biological level, this finding provides evidence that
class-IIHigh in untreated patients may harbor a subcategory
of HIV-infected cells expressing hundreds of viral RNA
copies per cell which likely represents productively
infected lymphocytes. Due to limitations in sample size
and resolution, transcriptional class-IIHigh could not be
further dissected. However, we observed that cells express-
ing significant amounts of vRNA-ex (class-IIIExtra, table 1),
a surrogate of productive HIV-infection [12,15,16],
occurred primarily before initiation of cART and were in
general rarer than class-IIHigh cells. Hence it is conceivable
that class-IIIExtra represents a productively infected sub-
category of class-IIHigh. Because the procedure for measur-
ing vRNA-ex necessitates nucleolytic digestion of
intracellular RNA and precludes simultaneous quantifica-
tion of intracellular MsRNA and UsRNA, co-localization
of class-IIIExtra  cells with class-IIHigh in a given sample
could not be tested. A minor subcategory of cells harbor-
ing vRNA-ex at very low levels (class-IIIR, table 1) was not
further characterized because it was likely that these cells
may not be HIV-infected but carry passively absorbed
plasma virus [12].
Kinetics of HIV-1 infected PBMC during cART
Turnover and kinetics of HIV-1+ PBMC were analyzed and
compared to the decay of plasma viremia as shown in fig-
ure 4 and table 2.
Plasma viremia during one year of cART showed a two
phase decline with an initial half-life (mean ± sem, days)
of 1.6 ± 0.2 d and a second phase with a half-life of 8.1 ±
2.3 d and suppression of viremia predominantly below
levels of 50 RNA copies/ml after 12 weeks of treatment
(figure 4A). The fact that plasma viremia of patients 111
and 112 were slightly elevated at study week 48 was not
considered a therapy failure, since plasma viremia
returned to levels below 50 copies/ml at the next visit and
remained suppressed during treatment for a further year
(data not shown).Retrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
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Whereas the total number of HIV-1 infected cells, as
assessed by HIV-1 DNA levels, experienced comparably
modest (74 ± 7%) and slow (t1/2 = 71 ± 60 d) decreases,
in general more than 90% of HIV-1 RNA+ cells decayed
rapidly after therapy initiation. HIV-infected cell cate-
gories of elevated transcriptional activity (class IIHigh,
class-IIIExtra) became frequently undetectable after initi-
ation of cART. However, their overall kinetics did not
unequivocally match plain single phase exponential
decay.
Outline of experimental strategy Figure 2
Outline of experimental strategy. A: Algorithm for combining limiting dilution of cells with RT-PCR. HIV-RNAs (in this 
example MsRNAs) of serial 5-fold dilutions of cells (left panel) are measured by RT-PCR (middle panel). Analysis of replicates 
of each dilution (right panel) reveals both the viral RNA content and the frequencies (estimated by 50% end-points) HIV-RNA+ 
cells. Applying criteria listed in table 1, in this case expression of either MsRNA-tatrev or MsRNA-nef (class-IIMedium) and 
expression of both MsRNA-tatrev and MsRNA-nef (class-IIHigh), cell classes differing in HIV-RNA content can be discerned. 
Specific HIV-RNA expression in each class of MsRNA+ cells can then be normalized by dividing MsRNA copies by the numbers 
of infected cells. In specimens positive for class-IIHigh cells which always contain class-IIMedium, the contribution of class-IIMedium 
needs to be considered (see formulas in panel B). Note that analysis of UsRNA contents in different cell-classes followed the 
same schemes. B: Analysis of specific MsRNA per-cell expression exemplified for patient 112. MsRNA expression (middle pan-
els) was normalized to the number of HIV-RNA+ cells (bottom panels) resulting in MsRNA expression per cell (top panels). 
The left three panels comprise specimens positive for class-IIMedium expression only. In the right three panels indicating speci-
mens positive for class-IIHigh MsRNA, the average contribution of class-IIMedium
+ cells (light grey bars) was subtracted from 
MsRNA copy numbers before normalization to the number of class-IIHigh + cells. The dotted lines in the top panels show the 
geometric means (meangm) of all data-points. Note that RNA copies per sample and frequencies of MsRNA+ cells (middle and 
bottom panels) are depicted in a linear scale which may result in column heights hardly discernible from zero. Formulas at the 
bottom describe the calculations performed. Bars show PCR results of separate replicates of PBMC dilutions, horizontal axes 
in the diagrams have no dimension
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Similarly, decays of class-ILow  and class-IIMedium  cells
tended to flatten out during the course of ART. Therefore,
half-lives were calculated assuming single phase decay
kinetics to a plateau. As expected, class-IIIExtra cells showed
rapid decays with an average half-life of 1.5 ± 0.6 d. Thus,
the cell class matching criteria for strong ongoing produc-
tive infection declined with the fastest rate of all four cell
classes. Half-lives of class IIHigh cells varied from 1–13
days. Their average half-life (5.4 ± 2.6 d) was similar to
that of class-ILow (3.2 ± 0.9 d) and class-IIMedium: (4.1 ±
0.66 d). Hence, HIV-RNA+ cells displaying basal viral tran-
scription decayed more slowly than productively infected
class-IIIExtra cells but with similar rates as class-IIHigh.
Throughout the course of therapy, HIV-RNA+ cells of class-
IIHigh and class-IIIExtra were largely outnumbered by cells of
low viral activity (class-ILow plus class-IIMedium >95% of
HIV-RNA+ cells) (figure 4G). Furthermore, contribution
of class-IIHigh to total cellular viral RNA burden (figure
4H) decreased from 44% at baseline to 30% during the
initial month of therapy and declined to <10% by study
week 24. Thus class-ILow and class-IIMedium cells dominated
the population of HIV-infected cells both in terms of cell-
numbers as well as in regards to total cellular viral RNA
burden.
Discussion
In the present study highly sensitive, patient matched
quantification of HIV-1 transcripts in total PBMC was
combined with endpoint analysis at a single cell level.
This enabled us to extend a previous analysis [22], in
which we have observed that the vast majority of infected
CD4-positive T-lymphocytes in peripheral blood in vivo
expressed viral RNA at levels insufficient for virus produc-
tion and could therefore be viewed as being of a latent
phenotype. Conversely, virus production appeared to be
confined to T-helper cells with HIV-mediated surface
CD4-downregulation. Whereas the former analysis cen-
tered on differentiation between the different cell-types
harboring viral RNA, the focus of the present work was,
irrespective of cellular lineage, on quantitative aspects of
HIV-transcription in vivo and its relation to viral decay
kinetics during antiretroviral therapy. Applying a plain
model and simple algorithms to analyze our complex
dataset, we attained to assign HIV-RNA+ cells to four tran-
scriptional categories, namely productively infected cells
carrying virions at their surface (class-IIIExtra), cells with
elevated viral transcriptional activity fuelled by Tat/Rev-
[20] and NEF-mediated [23] positive feedback (class-
IIHigh), cells expressing low levels of MsRNA and interme-
diate amounts of UsRNA (class-IIMedium) and cells express-
ing solely UsRNA (class-I). The latter two classes match a
strict definition of HIV-latency [15,22] since virion pro-
duction may likely be precluded in these cells due to their
low viral RNA content [15,22] and because these viral
transcripts may potentially be confined to the nucleus
[17].
Class-ILow viral RNA expression remained unchanged in a
comparison of specimens from treated and untreated
patients. Similarly, class-IIMedium  HIV-RNA content
appeared constant throughout the course of therapy,
whereas viral RNA expression of class-IIHigh cells was sig-
nificantly different in specimens before and during ART.
This suggests that a highly active subgroup in this stratum
was present in the absence of treatment which conceiva-
bly was identical or overlapping with the productively
infected class-IIIExtra.
The stratification of viral RNA expressing PBMC as exer-
cised in the present study provided only an approximate
categorical model for the continuous patterns of HIV-1
Table 1: Criteria to assign experimental specimens to viral transcriptional classes
No of unique specimensA for each patient
Class Presence of viral RNA Further criteria #103 #104 #110 #111 #112
ILow UsRNA+ M s R N A 2 64 61 75 73 4
IIMedium MsRNA+ Residual (<2 copies/specimen)B content of one type of 
MsRNA, Ms-tatrev or MsRNA-nef
45 51 56 12 32
IIHigh MsRNA-tatrev+ MsRNA-nef+ Significant (≥ 2 copies/specimen)B content of two types of 
MsRNA, MsRNA-tatrev and MsRNA-nef
28 33 19 5 15
IIIR vRNA-ex+ Residual (<2 copies/specimen)B content of vRNA-ex 14 1 5 4 5
IIIExtra vRNA-ex+ Significant (≥ 2 copies/specimen)B content of vRNA-ex 25 11 11 5 5
A Unique specimens in an expression class were defined as specimens devoid of cells with higher expression category: Thus unique class-ILow 
positive samples are devoid of class-IIMedium and class-IIHigh cells, unique class IIMedium specimens are devoid of class-IIHigh.
B Distinction between residual and significant viral RNA content was based on the following rationale: At the endpoint of dilution series of infected 
cells, specimens containing cells with viral RNA content close to one copy per cell will give PCR-positive readout only in single replicates with 
considerable variations in ct-values. These data were censored to one copy per specimen as described in Methods. Conversely PCR-readouts ≥ 2 
copies/specimen reflect measurements where quantification has been found to be reliable in this dataset.Retrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
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transcription likely occurring in vivo. Furthermore, it is
well possible that the cell classes characterized by different
cell-frequencies and viral transcriptional activity may not
reflect totally distinct and independent populations of
infected cells. Rather they may represent cells 'caught' in
different stages of the viral gene life cycle (figure 5, dis-
cussed further below) [24-28].
Notwithstanding the mathematical-model based nature
of our analysis, and the considerable overlap observed in
different classes of infected cells, we found good agree-
ment of our results with independent estimates of HIV-1
RNA expression as employed by Haase and colleagues
[29-33] who utilized sophisticated in situ hybridization to
asses HIV-transcription ex vivo in lymphoid tissue. In par-
ticular they described two types of HIV-RNA+ cells which
persist during cART with viral RNA content of ≤ 5 copies
[32,33] and cells expressing around 20 RNA copies [30].
These cell-types appear congruent to class-ILow cells and
class-IIMedium expressing on average 3.7 and 15 HIV-RNA
copies/cell respectively. Furthermore, productively HIV-
infected cells were estimated to contain on average 50–
100 viral RNA-copies in lymphoid tissues whereas average
levels of around 1000 RNA-copies were reported for virus
producing PBMC cultures [29,32]. This is highly reminis-
cent of our observations that class-IIHigh cells, which sub-
sume at least two subcategories, displayed average
expression levels of ~330 HIV-RNA copies/cell, which
Transcriptional signatures in HIV-infected PBMC in vivo Figure 3
Transcriptional signatures in HIV-infected PBMC in vivo. Per-cell viral RNA expression levels as calculated after assign-
ment of specimens to the transcriptional classes ILow, IIMedium and IIHigh (table 1). Only unique specimens devoid of cells of a 
higher expression category were analyzed in each expression class. Thus unique class-ILow positive samples are devoid of class-
IIMedium and class-IIHigh cells, unique class IIMedium specimens are devoid of class-IIHigh. Data were pooled from all patients because 
separate analyses of single patients showed similar distributions (data not shown). "Box and whiskers" show the ranges, medi-
ans and interquartile ranges of the data displayed by single symbols. Numbers below columns indicate medians (quartiles), p-
values above columns show significance levels of paired (Wilcoxon signed rank test) comparisons. *** indicates p-values < 
0.0001 of (unpaired) Mann-Whitney testing between neighbouring columns.
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were found to be elevated up to 846 copies/cell at base-
line.
All four HIV-RNA+ cell categories identified in the current
report showed rapid initial declines upon initiation of
cART. For cells of high transcriptional activity, this was in
concord with the notion that productively infected cells
may be associated with the 1st phase decay of plasma
viremia [3]. Indeed, the decay of class-IIIExtra cells pro-
ceeded rapidly and their average half-live (1.5 ± 0.6 d) was
virtually identical to the 1st phase half-live of free plasma
virus (1.6 ± 0.2 d). The half-lives of class-IIHigh cells were
slightly extended (5.4 ± 2.3 d). Unexpectedly kinetics of
class-IIHigh and, to some extent also of class-IIIExtra showed
hyperbolic rather than plain negative exponential shapes.
This finding may in part be explained by potential hetero-
geneities of cell classes as defined in our analysis. This
applies in particular to class-IIHigh cells which likely com-
prise both class-IIIExtra cells and a cell category of lower
transcriptional activity escaping immunological clearance
Kinetics of HIV-1 during cART Figure 4
Kinetics of HIV-1 during cART. A: Plasma viremia shown by log10 transformed plasma RNA copy numbers. B: Total HIV-1 
infected cells shown by log10 transformed copy numbers of HIV-1 DNA. C; D: Latently infected cells shown by log10 trans-
formed numbers of HIV-RNA+ PBMC of cell classes ILow (D) and IIMedium(C). E, F: Cells with increased viral transcription shown 
by log10 transformed numbers of class IIHigh (F) and IIIExtra (E). G: Mean (± sem) distribution of HIV-RNA+ cells during cART. H: 
Mean (± sem) contribution of different HIV-RNA+ cell classes to bulk cellular viral RNA as assessed by the sum of UsRNA and 
MsRNA in total RNA extracts. Data in A-F are depicted and connected with thin black lines for each patient (see symbols in 
the bottom of panel D). Dotted lines and the grey shaded bars in panels A and C-F show the estimated detection limit of limit-
ing dilution analyses for HIV-RNA+ PBMC. Symbols coinciding with detection limits signify time points with undetectable viral 
RNA. Thick black lines depict (log10 transformed) means (± sem) of the pooled data from all 5 patients. The grey line in panel 
A indicates the clinically used threshold of 50 RNA copy per ml.
112
111
110
104
103
%
 
o
f
 
b
u
l
k
c
e
l
u
l
a
r
H
I
V
-
R
N
A
IIIExtra
IIMedium
0 2 4 8 12 24 48
Weeks on cART
100
50
25
75
%
 
H
I
V
-
R
N
A
+
c
e
l
l
s
ILow
IIHigh
0 2 4 8 12 24 48
Weeks on cART
100
50
25
75
L
o
g
1
0
(
v
i
r
a
l
 
R
N
A
+
c
e
l
l
s
/
1
0
6
P
B
M
C
)
3
2
1
0
-1
Weeks on cART
0 2 4 8 12 24 48
D: ILow
4
3
2
1
0
-1
4 C:IIMedium
0 2 4 8 12 24 48
F: IIHigh
E: IIIExtra
L
o
g
1
0
(
c
o
p
i
e
s
/
1
0
6
P
B
M
C
)
3
2
1
0
-1
Weeks on cART
0 2 4 8 12 24 48
B: HIV-DNA
4
5
4
3
2
1
A: Plasma HIV-RNA
6
0
L
o
g
1
0
(
c
o
p
i
e
s
/
m
l
)
G HRetrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
Page 9 of 16
(page number not for citation purposes)
for longer time periods presumably due to moderate
expression of viral antigens as predicted by mathematical
models based on kinetics of plasma viremia [2,3].
Markedly contrary to initial expectations, class-ILow and
class-IIMedium kinetics proceeded similar to the course of
class-IIHigh  cells. Whereas it was anticipated that they
would show slow but steady exponential decline [2], we
observed substantial initial decays with average half-lives
of three to four days which were then followed by persist-
ence. Rapid initial decay of latently infected cells had been
previously observed in two reports by Blankson et al [34]
and Strain et al [35] in which CD4+ T-cells from acutely
infected patients were examined by viral outgrowth
Table 2: Turnover characteristics of HIV-1 RNA+ PBMC during cART
Cell numbersa Decaying cell fraction
Class Patient Baseline (N0) Plateau on cART (NP)( 1 - N P/N0)T 1/2 (days)b
ILow 103 470 39 91.7% 0.7
104 661 11 98.3% 3.8
110 582 29 95.0% 2.5
111 164 14 91.5% 2.5
112 89 11 87.6% 6.3
AllC: 393 ± 114 21 ± 5.6 93 ± 1.8% 3.2 ± 0.9
IIMedium 103 36 15 58.4% 4.6
104 125 2.3 98.2% 4.3
110 122 8.2 93.3% 6.3
111 33 0.1 99.7% 2.4
112 68 1.3 98.1% 3.2
AllC: 76 ± 20 5.4 ± 2.8 90 ± 7.9% 4.1 ± 0.7
IIHigh 103 14 ≤ 0.01 ≥ 99% 8.2
104 39 ≤ 0.01 ≥ 99% 2.5
110 4.9 ≤ 0.01 ≥ 99% 13
111 1.1 ≤ 0.01 ≥ 99% 1.1
112 18 ≤ 0.01 ≥ 99% 2.3
AllC: 15 ± 6.6 ≤ 0.01 ≥ 99% 5.4 ± 2.3
IIIExtra 103 25 ≤ 0.01 ≥ 99% 3.8
104 25 ≤ 0.01 ≥ 99% 1.7
110 11 ≤ 0.01 ≥ 99% 0.7D
111 1.7 ≤ 0.01 ≥ 99% 0.7D
112 0.9 ≤ 0.01 ≥ 99% 0.7D
AllC: 13 ± 5.3 ≤ 0.01 ≥ 99% 1.5 ± 0.6
Total HIV+ (HIV-1 DNA) 103 1808 326 82% 22
104 4030 370 91% 4.0
110 8533 2488 71% 174
111 5965 938 84% 17
112 10094 4853 52% 1.1
AllC: 6086 ± 14939 1795 ± 859 76 ± 6.8 44 ± 32
AHIV-1+ cells/106 PBMC
BDecay half-lives were calculated assuming one phase exponential decay to a plateau according to the equations; Nt = (N0 - NP) × e-Kt + NP; t = time 
(days), N0 = Cell number at baseline; NP = Cell number at plateau; Nt = Cell number at time t; T1/2 = LN(0.5)/(-K). Decay constants were 
constrained between 0 and 1, to exclude decay half-lifes shorter than 0.7 days to account for the limited data points available during periods of 
initial decay
CMean ± standard error (sem) of data from all five patients.
DExact determination by fitting of class IIIExtr could only be achieved for patients 103 and 104 for which minimally three data-points above detection 
threshold were available. Half-lives of patients 110, 111 and 112 with one or two data points above threshold were estimated as 0.7 days (K = 1).Retrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
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A model of the turnover of HIV-RNA+ cells during the viral life-cycle Figure 5
A model of the turnover of HIV-RNA+ cells during the viral life-cycle. The displayed cells symbolize HIV-1 infected 
cells of classes ILow (blue), IIMedium (blue/magenta), IIHigh (magenta/red) and IIIExtra (brown). Inserts within the circle symbolize the 
kinetics of each cell class during cART. Viral particles are depicted as black/yellow stars with the enclosed genomic RNA 
(vRNA-ex) in red. Viral proteins are shown as red/yellow diamonds, ellipses, circles and cylinders. Viral intracellular RNA is 
displayed as blue (UsRNA) or red (MsRNA) lines. Buckled arrows attached to viral particles signify the direct or indirect influ-
ences of activation due to ongoing viral replication and the presence of viremia on the viral life cycle [24,43-46]. A: Immune 
activation can promote post-entry events in resting CD4+ T cells harboring free viral cDNA such as integration and initiation 
of viral transcription [25,26,43]. B: Nonspecific immune activation can induce transcription in latently infected cells [27,47] and 
may result in a acceleration of viral replication [15,45]. C: CD8 T-cell mediated cytoxicity (CTL) [39,40] and humoral immunity 
[41], such as antibody-dependent cellular cytotoxicity (ADCC) and complement effector functions [28], are prone to attack 
HIV-1 infected cells expressing viral antigens. D: After initiation of cART, the viral life cycle is slowed primarily by preventing 
new infections but also by decreasing immune activation which results in decelerated rates of integration, detained induction of 
latency and reduced immune mediated HIV-specific cytotoxicity (A, B, C).
HIV-DNA
-
-
HIV-DNA
-
-
HIV-DNA
-
-
HIV-DNA
L
o
g
(
n
)
Æ
Time Æ
IIMedium
L
o
g
(
n
)
Æ
Time Æ
ILow
New infections
CTL
ADCC
cART
Time Æ
IIIExtra
L
o
g
(
n
)
Æ
IIHigh
A
B
B
B
D
CRetrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
Page 11 of 16
(page number not for citation purposes)
assays. In consideration of the in vivo scarcity of provirus
inducible by in vitro outgrowth assays [8], the cell types
studied in these earlier reports may not be totally super-
posable to the two classes of latently infected cells identi-
fied in the present study. Hence, the half-lives calculated
in the present analysis (0.7–6.3 days) were generally
shorter than those reported by Blankson and colleagues (≥
6 days). Nevertheless, our observation that two types of
HIV-RNA+ latently infected cells may shift from rapid to
slower decay during the course of antiretroviral treatment
appears to hold true also for cell subsets inducible by in
vitro outgrowth assays. Such apparent variability in turno-
ver of latently infected cells may be interpreted in two
ways:
As discussed for class-IIHigh, also cell-class-ILow and class-
IIMedium may be heterogeneous in terms of virological sub-
categories but also in reference to cellular lineage and/or
in terms of their current state in the viral life cycle. Thus,
class-ILow and class-IIMedium may comprise cell-types with
rapid turnover and long lived cells. Whereas the latter may
be allocated to resting HIV-infected CD4+ T-cells [36], the
main candidates for weakly virus transcribing cells with a
short half-life could be newly infected cells in a labile state
of preintegration latency [9,37].
However, HIV-1 DNA levels, which have been reported to
be dominated by nonintegrated molecules in PBMC of
untreated patients [38], showed a much less pronounced
decay than HIV-infected cells expressing viral RNA and no
correlation with frequencies of class-ILow and class-IIMedium
cells (Spearman R = 0.26, p > 0.12), which were signifi-
cantly correlated with each other (Spearman R = 0.67, p <
0.0001). This suggests that HIV-RNA+ latently infected
cells decayed with different kinetics than the majority of
HIV-1 infected cells harboring nonintegrated viral DNA.
Thus, the fast turnover of unintegrated HIV-DNA may not
entirely account for the rapid initial decay of HIV-RNA+
cells.
Therefore it is conceivable that turnover rates of HIV-1
infected cells may be intrinsically variable. In particular,
they may be influenced by their cellular and humoral
environment, which differs under conditions of cART and
during viremia. Attenuation of antigenic stimulation due
to cART results in declines of cellular [39,40] and humoral
anti-HIV responses [41], which may decrease death rates
of HIV-infected cells expressing viral antigens. Further-
more, generalized immune-activation by HIV-1 [42-46]
may enhance viral replication itself by facilitating the tran-
sition from preintegration to genuine chromosomal pro-
viral integration [37], or by activation of transcriptionally
dormant provirus [47]. By accelerating the turnover of
latently infected cells and driving the viral life cycle
towards productivity (figure 5), feedback loops of various
effects of HIV-1 on infected cells may potentiate viral rep-
lication [15,45]. In consequence of the decline of produc-
tively infected cells and of viremia, attenuation of antiviral
immunity and systemic immune activation may contrib-
ute to the observed mitigation in turnover of latently
infected cells.
Conclusion
The present study was highly comprehensive in terms of
PCR-targets and sample size despite limitations in patient
number and in statistical resolution between different cell
classes. Thus, it revealed important novel features of HIV-
1 transcription and its relation with viral dynamics in
vivo.
In summary, at least four categories of HIV-RNA+ cells
could be identified and assigned to distinct viral transcrip-
tion patterns. Among these cell classes, latently infected
cells represent the majority of HIV-1 infected PBMC both
in the absence of treatment and during cART. This empha-
sizes the crucial role that latent HIV-1 reservoirs play not
only in the maintenance of viral persistence during cART
but, as precursors of productively infected cells, also
under conditions of ongoing viral replication.
Foremost, we have gained evidence suggesting that at least
two types of latently HIV-1 infected cells after initiation of
cART decay with kinetics similar to those of productively
infected cells. These rapid decays may be shaped by cellu-
lar and humoral immune responses against HIV and by
HIV-induced activation which prevail before and early
after initiation of cART but wither away when viral repli-
cation is stably suppressed. Verifying the hypothesis that
decay of latently HIV-infected cells may not be constant
but prone to influences from their cellular and humoral
environment and identifying the factors governing the
turnover of latently infected cells may help to devise novel
therapeutic strategies to pursue the as yet elusive aim of
eradicating HIV-1.
Methods
Patients and specimens
Five chronically HIV-1 infected therapy naïve patients ini-
tiating cART according to standard treatment guidelines
(patient nr 103, 104, 110, 111, 112) were enrolled after
informed consent was obtained. The study was approved
by the ethics committee of the University Hospital Zürich.
Patients were treated with zidovudine plus lamivudine
(300 mg BID), and ritonavir boosted lopinavir (100/400
mg BID), except for patient 103 who replaced ritonavir/
lopinavir by efavirenz (daily 1 × 600 mg) at week 32.
Median (range) baseline clinical parameters were
147(116; 262) CD4 T-lymphocytes/μl blood and 158'000Retrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
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(14'300; 203'500) viral RNA copies/ml plasma. PBMC
were purified as described [15] and aliquots (n = 8–14)
were distributed into equal proportions ranging from 1–4
million cells/tube. Further serial five-fold dilutions of
PBMC (12–24 replicates each; 5×, 25×, 125×, 625×,
3125× dilutions) were prepared and diluted PBMC were
supplemented with uninfected CEM cells [48] (3 × 105
cells/aliquot) to avert cell loss in dilutions. Cells were
stored at -80°C as dry pellets.
Nucleic acid analysis
RNA was extracted (RNeasy, Qiagen Hombrechtikon,
CH) using two protocols in parallel [12,15]. Total PBMC
RNA was extracted by the standard procedure [49] and
specific isolation of PBMC-associated extracellular, virion-
enclosed HIV-RNA (vRNA-ex) was performed by nucleo-
lytic digestion of cellular nucleic acids while RNA
enclosed in viral envelopes remain protected [12,15,18].
RNA was eluted in a volume of 0.1 ml.
PCR primers and fluorescent probes mapping to the gag
gene were used to quantify UsRNA, vRNA-ex and HIV-
DNA [50]. PCR strategies to quantify viral nucleic acids
are shown in figure 6A. Analysis of MsRNA was performed
[15] utilizing a PCR for MsRNA encoding Nef, Tat and Rev
(MsRNA-total) and an assay for MsRNA encoding Tat and
Rev (MsRNA-tatrev). Subtracting copy numbers of
MsRNA-total from MsRNA-tatrev allowed for calculation
of MsRNA encoding Nef (MsRNA-nef) [15]. Some speci-
mens with very low HIV-RNA content, showed MsRNA-
total copy numbers smaller or equal to MsRNA-tatrev, in
this case MsRNA-nef was assumed being undetectable.
Since values for MsRNA-tatrev and MsRNA-nef showed
similar kinetics, data analysis of the sum of both parame-
ters, referred to as MsRNA, was performed. HIV-1 PCR
primers used were individually adjusted to their binding
sites for each patient's predominant quasispecies as
described [22] (table 3). Real time RT PCR assays were
performed using a protocol which approached single copy
sensitivity as previously reported [15,18,22] and as exem-
plified in figure 6B. HIV-DNA was amplified as described
[22]. PCR was performed in duplicate reactions using 10–
20 μl RNA per specimen. PCR data were interpolated from
patient-matched RNA standard-curves [22]. HIV-RNA in
plasma was measured using Amplicor HIV-Monitor ver-
sion 1.5 (Roche Diagnostics, Basel, Switzerland).
Calculations and statistics
Statistics were performed using GraphPad Prism4.0 soft-
ware (GraphPad Software, San Diego, CA).
RNA copy-numbers were calculated as the mean of dupli-
cate PCR measurements, extrapolated to copy numbers
per tube (5–10-fold multiplication) and normalized to
the input of PBMC. In HIV-RNA+ specimens near the
detection limit of the test, quantification of HIV-RNA was
censored to avoid gross overestimation: If only one dupli-
cate PCR was positive and/or nominal copy numbers were
below 1 copy per reaction, it was assumed that 1 RNA
copy had been present per tube.
Stratification and assignment of specimens to different
transcriptional classes were executed according to criteria
compiled in table 1. Frequencies of HIV-RNA+ cells were
calculated by 50% endpoint analysis [22] according to the
method described by Muench and Reed [51]. Specific
RNA contents in different transcriptional classes were cal-
culated by a stepwise "bottom up" approach in which the
contribution of the different classes of HIV-RNA express-
ing cells was dissected as described in figure 2: Since cells
of frequent transcriptional classes co-occurred with cells
of rarer classes, the contribution of the first had to be sub-
tracted from the total copy numbers to calculate the copy
numbers of the latter. After this subtraction HIV-RNA
copy numbers in a given specimen were normalized to its
content of HIV-RNA+ cells. Rarely this resulted in nomi-
nally negative values which were censored to 1 copy per
cell, to allow further analyses using logarithmic transfor-
mation.
Statistical comparisons between groups were performed
using nonparametric tests; the Mann-Whitney test for
unpaired data-sets, Wilcoxon signed rank tests for paired
analyses and, when adjustment for multiple testing was
applied, one way Anova and a Friedman post test analyz-
ing all possible combinations was applied.
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PCR-Quantification of HIV-RNAs Figure 6
PCR-Quantification of HIV-RNAs. A: Location of primers and probes used for PCR. Labeled bars depict viral genes and 
the unlabelled bars below show exons of viral transcripts quantified as previously described [15]. White: genomic RNA span-
ning the entire transcriptional unit, grey: multiply spliced RNAs encoding tat and rev (dark grey) or nef (light grey). Arrows 
show the location of PCR primers and barbells the positioning of fluorescent probes. Note that MsRNA-nef was calculated as 
the difference of copy number for MsRNA-total and MsRNA-tatrev as described previously [15] (formula indicated in italic let-
ters). B: Performance of PCR assays. Patient-specific in vitro transcribed UsRNA and MsRNA prepared from templates isolated 
from patient 104 and quantified photometrically was subjected to RT-PCR using patient specific primers as listed in table 3. 
Ten-fold dilutions ranging from 5 × 107 – 5 copies were run in replicates of two (5 × 107 – 5 × 104 copies) or four (5000–5 cop-
ies). Upper panels show amplification plots (mean ± standard error) with the amplification threshold (broken lines) as calcu-
lated by default settings of the software used (i-cycler, Biorad). In the lower panels log-transformed copy numbers were 
plotted against cycle-threshold (ct) values of each replicate. Linear regression analysis as shown by the resulting equations for 
black lines (broken lines depict 95% confidence intervals) revealed high correlation coefficients of standard curves. PCR effi-
ciencies as deduced from slopes ranged from 89%–96%. Sensitivities of PCR assays (grey vertical lines, italic numbers) were 
estimated by determination of 50% endpoints [51]. All assays approached single copy sensitivities as previously documented 
[15,22] with assays for MsRNA-tatrev (1.6 copies) being the most sensitive ones followed by PCR for UsRNA/vRNA-ex (2.3 
copies) and the assay for MsRNA-total (5 copies). PCR assays for the other patients performed similarly (data not shown).
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Table 3: Patient matched PCR primers
Position C
Primer-IDa Functionb 5' 3' Sequence D Analysis of patient noE
Ts5'gag Sense-primer
UsRNA/vRNA-ex
1372 1397 CAAGCAGCCATGCAAATGTTAAAAGA 103, 104, 1105, 111
CAAGCAGCTATGCAAATGTTAAAAGA 112
Boe3tq Antisense-probe
UsRNA/vRNA-ex
1430 1405 f-CTATCCCATTCTGCAGCTTCCTCATT-q 104, 110E, 111, 112
f-TCTATCCCATTCTGCAGCTTCTTCATT-q 103
Boe2 Antisense-primer
UsRNA/vRNA-ex
1488 1467 TCCCCTTGGTTCTCTCATCTGG 104, 110E, 111, 112
TCCCCTTGGTTCCCTTATCTGG 103
Skcc1b cDNA-primer,
UsRNA/vRNA-ex
1513 1486 TACTAGTAGTTCCTGCTATGTCACTTCC 103, 110E, 111, 112
TCCCCTTGGTTCCCTTATCTGG 104
Mf1 Sense-primer
MsRNA-tatrev
5956 5979 CTTAGGCATCTCCTATGGCAGGAA 103, 104, 111, 112
ATTAGGCATCTCCTATGGCAGGAA 110E
Ts5'allspl Sense-primer
MsRNA-total
5978 6001 AAGAAGCGGAGACAGCGACGAAGA 103, 104
Mf84 Sense-primer
MsRNA-total
6012 6045 ACAGTCAGACTCATCAAGTTTCTCTATCAAAGCA 111
ACAGTAAGACTCaTCAAGCTTCTCTATCAAAGCA 110E
CAGTCAGACTCATCAAGCTTCTCTATCAAAGCA 112
mf2tq Antisense-probe
MsRNA-total
MsRNA-tatrev
8421 8399 f-TTCCTTCGGGCCTGTCGGGTCCC-q 104
f-TTCCTTCGGGCCTGTCTGGTCCC-q 103
Mf226tq Sense-Probe
MsRNA-total
MsRNA-tatrev
8397 8414 f-AGGGGACCCGACAGGCCC-q 110E, 112
f-AGGGGACGACCCGACAGG-q 111
Mf83 Antisense/cDNA-
primer
MsRNA-total
MsRNA-tatrev
8459 8433 GGATCTGTCTCTGTCTCTCTCTCCACC 111
TGATCTGCCTCTGTCTTGCTCTCCACC 103
GGATGTGTCTCTGTCTCTGTCTCCACC 104
TGATGTGTCTCTGTCTCTCTCTCCACC 110E
GGATCTGTCTCTGTCTCTGTCCCCACC 112
A ID denominates identification of primers according to internal nomenclature in the authors laboratory[22].
B Oligonucleotide function; Sense/antisense-primer: oligonucleotide of the respective polarity used for amplification, sense/antisense probe: 
fluorogenic probe of the respective polarity used for detection of genuine amplification products, cDNA-primer: oligonucleotide of negative 
polarity used for reverse transcription prior to amplification. In assays for UsRNA/vRNA-ex separate cDNA and antisense primers were used 
except for patient 112 (skkcc1b was used for cDNA synthesis and PCR). In assays for MsRNAs, the same primer was used for reverse transcription 
and amplification.
C Numbering on the Hxb2 genome according to the software provided by the Los Alamos HIV database; (SEQUENCE LOCATOR, http://
www.hiv.lanl.gov).
D Sequences are indicated 5' to 3' from left to right. Underlined positions show deviation from the standard sequence (HXB2 or clade B consensus) 
(indicated in bold letters). f = Fluorescein-moiety attached to the DNA-probe, q= Fluorescence quenching moiety attached to the DNA-probe.
E Note that PCR primers of patient 110 have been previously reported [22]. In this earlier study, in which patient 110 has been referred as "patient 
08", different time points and specimens have been analyzed with a focus on the cellular origin of HIV-1 transcription.Retrovirology 2008, 5:107 http://www.retrovirology.com/content/5/1/107
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